4D Molecular Therapeutics FDMT Issuance Of Common Stock Upon Exercise Of Stock Options

Other financials

Revenue$3.0M+21,664%

Operating income-$73.6M-37.3%

Net income-$68.8M-43.3%

EPS (diluted)-$1.01-17.4%

Cash & equivalents$72.5M-45.7%

Total debt$20.5M-13.9%

Total equity$451.8M-3.8%

Total assets$512.9M-0.5%

Operating cash flow-$68.1M-42.6%

CapEx--100%

Free cash flow-$68.1M-40.8%

Market cap$602.22M+215%

Enterprise value$550.27M+574%

P/S6.8×-8,306×

Operating margin-220.1%-110pp

Net margin-174,314.2%-62,763pp

FCF margin-154,209.2%-53,057pp

Return on equity-45.4%+29.8pp

Debt / equity0×0.0×

Current ratio9.3×-3.0×

Reported directly by 4D Molecular Therapeutics in its filing.

Tagged under the XBRL concept fdmt:IssuanceOfCommonStockUponExerciseOfStockOptions.

The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is 4D Molecular Therapeutics's issuance of common stock upon exercise of stock options?: 4D Molecular Therapeutics (FDMT) reported issuance of common stock upon exercise of stock options of $1.67M in Q1 2026.